Enhancement of humoral and cellular immunity with an anti-glucocorticoid- induced tumour necrosis factor receptor monoclonal antibody

Immunology

Volumn 130, Issue 2, 2010, Pages 231-242

  Ponte, Jose F ^a   Ponath, Paul ^a   Gulati, Reema ^a   Slavonic, Michael ^a   Paglia, Michael ^a   O'Shea, Adam ^a   Tone, Masahide ^b   Waldmann, Herman ^b   Vaickus, Louis ^a   Rosenzweig, Michael ^a  

^a Tolerx Inc   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Adjuvant; Glucocorticoid induced tumour necrosis factor receptor; Haemagglutinin; T helper type 1 response; Tumour necrosis family receptor superfamily

Indexed keywords

GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; HEMAGGLUTININ; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN G2B ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2F8; NEUTRALIZING ANTIBODY; OVALBUMIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS LINKING; DRUG EFFICACY; DRUG INDICATION; ENZYME LINKED IMMUNOSPOT ASSAY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; HEMAGGLUTININS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; MACROPHAGES; MICE; MICE, INBRED BALB C; OVALBUMIN; RATS; RECEPTORS, NERVE GROWTH FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR; TH1 CELLS;

EID: 77952013354     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2009.03228.x     Document Type: Article

References (78)

1. Fraser CK, Diener KR, Brown MP, Hayball JD. Improving vaccines by incorporating immunological coadjuvants. Expert Rev Vaccines 2007 6 : 559 578.
2. Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004 82 : 488 496. (Pubitemid 39421058)
3. Vogel FR. Improving vaccine performance with adjuvants. Clin Infect Dis 2000 30 (Suppl. 3 S266 70.
4. Glenny ATPC, Waddington H, Wallace V. The antigenic value of toxoid precipitated by potassium-alum. J Pathol Bacteriol 1926 29 : 38 45.
5. Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol 2009 30 : 23 32.
6. Brewer JM, Conacher M, Hunter CA, Mohrs M, Brombacher F, Alexander J. Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. J Immunol 1999 163 : 6448 6454.
7. Grun JL, Maurer PH. Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses. Cell Immunol 1989 121 : 134 145.
8. Plotkin SA. Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J 2001 20 : 63 75.
9. Gupta RK, Siber GR. Adjuvants for human vaccines - current status, problems and future prospects. Vaccine 1995 13 : 1263 1276.
10. Lindblad EB. Aluminium adjuvants - in retrospect and prospect. Vaccine 2004 22 : 3658 3668.
11. Sela M, Hilleman MR. Therapeutic vaccines: realities of today and hopes for tomorrow. Proc Natl Acad Sci U S A 2004 101 (Suppl. 2 14559. (Pubitemid 39346723)
12. Vandepapeliere P. Therapeutic vaccination against chronic viral infections. Lancet Infect Dis 2002 2 : 353 367. (Pubitemid 34595975)
13. Dredge K, Marriott JB, Todryk SM, Dalgleish AG. Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy. Cancer Immunol Immunother 2002 51 : 521 531. (Pubitemid 35232001)
14. Ikeda H, Chamoto K, Tsuji T, Suzuki Y, Wakita D, Takeshima T, Nishimura T. The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci 2004 95 : 697 703. (Pubitemid 39335087)
15. Moingeon P, Haensler J, Lindberg A. Towards the rational design of Th1 adjuvants. Vaccine 2001 19 : 4363 4372. (Pubitemid 32718658)
16. Barr TA, Carlring J, Heath AW. Co-stimulatory agonists as immunological adjuvants. Vaccine 2006 24 : 3399 3407.
17. Hodge JW, Greiner JW, Tsang KY et al. Costimulatory molecules as adjuvants for immunotherapy. Front Biosci 2006 11 : 788 803.
18. Serghides L, Vidric M, Watts TH. Approaches to studying costimulation of human antiviral T cell responses: prospects for immunotherapeutic vaccines. Immunol Res 2006 35 : 137 150. (Pubitemid 44547509)
19. Ward RC, Kaufman HL. Targeting costimulatory pathways for tumor immunotherapy. Int Rev Immunol 2007 26 : 161 196.
20. Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005 23 : 23 68. (Pubitemid 40563164)
21. Croft M. Costimulation of T cells by OX40, 4-1BB, and CD27. Cytokine Growth Factor Rev 2003 14 : 265 273. (Pubitemid 36693146)
22. Kober J, Leitner J, Klauser C et al. The capacity of the TNF family members 4-1BBL, OX40L, CD70, GITRL, CD30L and LIGHT to costimulate human T cells. Eur J Immunol 2008 38 : 2678 2688.
23. Ji HB, Liao G, Faubion WA, Abadia-Molina AC, Cozzo C, Laroux FS, Caton A, Terhorst C. Cutting edge: the natural ligand for glucocorticoid-induced TNF receptor-related protein abrogates regulatory T cell suppression. J Immunol 2004 172 : 5823 5827. (Pubitemid 38621178)
24. + regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002 3 : 135 142. (Pubitemid 34141443)
25. + T cells. J Immunol 2004 173 : 5008 5020. (Pubitemid 39387783)
26. + T cells. J Leukoc Biol 2004 75 : 785 791. (Pubitemid 38580058)
27. + T cells confers resistance to suppression by virus-induced regulatory T cells. J Immunol 2008 180 : 5267 5274.
28. + T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 2005 105 : 2845 2851. (Pubitemid 40446278)
29. + Tregs. Blood 2007 110 : 2501 2510. (Pubitemid 47523172)
30. Morel Y, Truneh A, Sweet RW, Olive D, Costello RT. The TNF superfamily members LIGHT and CD154 (CD40 ligand) costimulate induction of dendritic cell maturation and elicit specific CTL activity. J Immunol 2001 167 : 2479 2486. (Pubitemid 32768873)
31. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998 393 : 480 483. (Pubitemid 28292196)
32. Wilcox RA, Chapoval AI, Gorski KS et al. Cutting edge: expression of functional CD137 receptor by dendritic cells. J Immunol 2002 168 : 4262 4267. (Pubitemid 34441322)
33. Ronchetti S, Zollo O, Bruscoli S, Agostini M, Bianchini R, Nocentini G, Ayroldi E, Riccardi C. GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations. Eur J Immunol 2004 34 : 613 622. (Pubitemid 39255908)
34. + immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2002 16 : 311 323. (Pubitemid 34211969)
35. Gurney AL, Marsters SA, Huang RM et al. Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR. Curr Biol 1999 9 : 215 218.
36. Kwon B, Yu KY, Ni J et al. Identification of a novel activation-inducible protein of the tumor necrosis factor receptor superfamily and its ligand. J Biol Chem 1999 274 : 6056 6061. (Pubitemid 29111009)
37. Li M, Miyagawa J, Moriwaki M et al. Analysis of expression profiles of islet-associated transcription and growth factors during beta-cell neogenesis from duct cells in partially duct-ligated mice. Pancreas 2003 27 : 345 355. (Pubitemid 37337902)
38. Ronchetti S, Nocentini G, Riccardi C, Pandolfi PP. Role of GITR in activation response of T lymphocytes. Blood 2002 100 : 350 352. (Pubitemid 35177469)
39. So T, Lee SW, Croft M. Tumor necrosis factor/tumor necrosis factor receptor family members that positively regulate immunity. Int J Hematol 2006 83 : 1 11. (Pubitemid 43172735)
40. Tone MTY, Adams E, Yates SF, Frewin MR, Cobbold SP, Waldmann H. Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells. Proc Natl Acad Sci U S A 2003 100 : 15059 15064. (Pubitemid 37518016)
41. + T cells in graft-versus-host disease. J Exp Med 2004 200 : 149 157. (Pubitemid 38982174)
42. Spinicelli S, Nocentini G, Ronchetti S, Krausz LT, Bianchini R, Riccardi C. GITR interacts with the pro-apoptotic protein Siva and induces apoptosis. Cell Death Differ 2002 9 : 1382 1384. (Pubitemid 36097709)
43. Esparza EM, Arch RH. Glucocorticoid-induced TNF receptor functions as a costimulatory receptor that promotes survival in early phases of T cell activation. J Immunol 2005 174 : 7869 7874.
44. Nocentini G, Giunchi L, Ronchetti S, Krausz LT, Bartoli A, Moraca R, Migliorati G, Riccardi C. A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis. Proc Natl Acad Sci U S A 1997 94 : 6216 6221. (Pubitemid 27270664)
45. Zhan Y, Brown LE, Deliyannis G et al. Responses against complex antigens in various models of CD4 T-cell deficiency: surprises from an anti-CD4 antibody transgenic mouse. Immunol Res 2004 30 : 1 14. (Pubitemid 38998646)
46. + T-cell responses and tumor immunity. Cancer Res 2006 66 : 4904 4912.
47. Ramirez-Montagut T, Chow A, Hirschhorn-Cymerman D et al. Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. J Immunol 2006 176 : 6434 6442. (Pubitemid 43787825)
48. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 2004 200 : 771 782.
49. + regulatory T cells. J Exp Med 2005 202 : 885 891. (Pubitemid 41396888)
50. + effector T cells in mediating agonistic anti-GITR mAb-induced-immune activation and tumor immunity in CT26 tumors. J Immunol 2007 179 : 7365 7375.
51. + T cells by regulatory T cells during persistent retroviral infection. Immunity 2004 20 : 293 303. (Pubitemid 38388231)
52. La S, Kim E, Kwon B. In vivo ligation of glucocorticoid-induced TNF receptor enhances the T-cell immunity to herpes simplex virus type 1. Exp Mol Med 2005 37 : 193 198. (Pubitemid 40992734)
53. Diehl L, den Boer AT, Schoenberger SP, van der Voort EI, Schumacher TN, Melief CJ, Offringa R, Toes RE. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med 1999 5 : 774 779. (Pubitemid 29318611)
54. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE, Mittler RS, Chen L. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997 3 : 682 685. (Pubitemid 27264981)
55. + T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med 1999 5 : 780 787. (Pubitemid 29318612)
56. Weinberg AD, Rivera MM, Prell R et al. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol 2000 164 : 2160 2169. (Pubitemid 30108775)
57. Bertram EM, Lau P, Watts TH. Temporal segregation of 4-1BB versus CD28-mediated costimulation: 4-1BB ligand influences T cell numbers late in the primary response and regulates the size of the T cell memory response following influenza infection. J Immunol 2002 168 : 3777 3785. (Pubitemid 34298377)
58. Munks MW, Mourich DV, Mittler RS, Weinberg AD, Hill AB. 4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine. Immunology 2004 112 : 559 566.
59. Xiao C, Jin H, Hu Y et al. Enhanced protective efficacy and reduced viral load of foot-and-mouth disease DNA vaccine with co-stimulatory molecules as the molecular adjuvants. Antiviral Res 2007 76 : 11 20. (Pubitemid 47176689)
60. + regulatory T cells mediated by GITR molecules. Immunol Lett 2008 121 : 97 104.
61. Robert G, Webster SK, World Health Organization Global Influenza Programme. WHO manual on animal influenza diagnosis and surveillance.
62. Benne CA, Harmsen M, van der Graaff W, Verheul AF, Snippe H, Kraaijeveld CA. Influenza virus neutralizing antibodies and IgG isotype profiles after immunization of mice with influenza A subunit vaccine using various adjuvants. Vaccine 1997 15 : 1039 1044. (Pubitemid 27308583)
63. Hocart MJ, Mackenzie JS, Stewart GA. The immunoglobulin G subclass responses of mice to influenza A virus: the effect of mouse strain, and the neutralizing abilities of individual protein A-purified subclass antibodies. J Gen Virol 1989 9 : 2439 2448.
64. Shibaki A, Katz SI. Induction of skewed Th1/Th2 T-cell differentiation via subcutaneous immunization with Freund's adjuvant. Exp Dermatol 2002 11 : 126 134. (Pubitemid 36934630)
65. Billiau A, Matthys P. Modes of action of Freund's adjuvants in experimental models of autoimmune diseases. J Leukoc Biol 2001 70 : 849 860. (Pubitemid 33151123)
66. Sun Y, Lin X, Chen HM, Wu Q, Subudhi SK, Chen L, Fu YX. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. J Immunol 2002 168 : 1457 1465. (Pubitemid 34094519)
67. Sytwu HK, Lin WD, Roffler SR et al. Anti-4-1BB-based immunotherapy for autoimmune diabetes: lessons from a transgenic non-obese diabetic (NOD) model. J Autoimmun 2003 21 : 247 254.
68. Tao MH, Morrison SL. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol 1989 143 : 2595 2601.
69. Mosmann TR, Coffman RL. Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv Immunol 1989 46 : 111 147.
70. Neuberger MS, Rajewsky K. Activation of mouse complement by monoclonal mouse antibodies. Eur J Immunol 1981 11 : 1012 1016. (Pubitemid 12212156)
71. Gessner JE, Heiken H, Tamm A, Schmidt RE. The IgG Fc receptor family. Ann Hematol 1998 76 : 231 248. (Pubitemid 28321079)
72. Kipps TJ, Parham P, Punt J, Herzenberg LA. Importance of immunoglobulin isotype in human antibody-dependent, cell-mediated cytotoxicity directed by murine monoclonal antibodies. J Exp Med 1985 161 : 1 17. (Pubitemid 15169717)
73. Takai T, Li M, Sylvestre D, Clynes R, Ravetch JV. FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell 1994 76 : 519 529. (Pubitemid 24064172)
74. Huber VC, Lynch JM, Bucher DJ, Le J, Metzger DW. Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J Immunol 2001 166 : 7381 7388. (Pubitemid 32525614)
75. Aurisicchio L, Peruzzi D, Conforti A et al. Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9. Clin Cancer Res 2009 15 : 1575 1584.
76. Durso RJ, Andjelic S, Gardner JP et al. A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses. Clin Cancer Res 2007 13 : 3999 4008. (Pubitemid 47037608)
77. Patel M, Xu D, Kewin P, Choo-Kang B, McSharry C, Thomson NC, Liew FY. Glucocorticoid-induced TNFR family-related protein (GITR) activation exacerbates murine asthma and collagen-induced arthritis. Eur J Immunol 2005 35 : 3581 3590. (Pubitemid 43025538)
78. Subbarao K, Murphy BR, Fauci AS. Development of effective vaccines against pandemic influenza. Immunity 2006 24 : 5 9. (Pubitemid 43077193)